BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to discuss the company’s second quarter financial results.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that results from its Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).

Gannex Pharma Co., Ltd. (“Gannex”), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98 patients with primary biliary cholangitis (PBC) in the Phase II clinical trial of ASC42, a novel Farnesoid X receptor (FXR) agonist.

BioCity Biopharma announced the dosing of the first patient in a Phase 1a/1b clinical trial of its first-in-class CDH3 antibody drug conjugate, BC3195 in China.

Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer, has been accepted for review by the National Medical Products Administration.

Anbio, a leading provider of innovative diagnostic Solutions, proudly presents the Anbio LAMP Solution, an innovative point-of-care Solution designed for easy-to-use but elegantly sophisticated qualitative diagnostics.

Today, Virgin Pulse, the leading global digital-first health, wellbeing, and navigation company, unveiled the results of a one-year, 90,000+ member analysis that demonstrates that its Homebase for Health® platform is effective in driving biometric improvement for members with obesity, hypertension, or high blood sugar.

Kintor Pharmaceutical Limited announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.